Bluejay director granted 100K options tied to FDA

Bluejay Diagnostics, Inc. (BJDX) reported that director Svetlana Dey received a grant of 100,000 stock options to purchase common stock at an exercise price of $2.075 per share.

Rhea-AI Filing Summary

Bluejay Diagnostics, Inc. (BJDX) reported that director Svetlana Dey received a grant of 100,000 stock options to purchase common stock at an exercise price of $2.075 per share. The options vest and become exercisable on the first anniversary of the grant, but cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. These options expire on August 17, 2031, and following this grant Dey holds 100,000 options directly.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Dey Svetlana

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 contracts (Direct)

Footnotes (1)

1. F1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

Key Figures

Options Granted: 100,000 options Exercise Price: $2.075 per share Underlying Shares: 100,000 shares +2 more

5 metrics

Options Granted 100,000 options Stock Option (Right to Buy) grant to director Svetlana Dey

Exercise Price $2.075 per share Conversion or exercise price for the granted stock options

Underlying Shares 100,000 shares Common Stock underlying the granted stock options

Expiration Date August 17, 2031 Expiration of the granted stock options

Total Options After Grant 100,000 options Total options held directly by Dey following the transaction

Key Terms

out-of-the-money stock options, point-of-care testing device, U.S. Food and Drug Administration, vest and become exercisable

4 terms

out-of-the-money stock options financial

"Represents out-of-the-money stock options that vest and become exercisable"

point-of-care testing device medical

"approval of the issuer's Symphony IL-6 point-of-care testing device"

U.S. Food and Drug Administration regulatory

"unless and until the U.S. Food and Drug Administration shall have granted clearance"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

vest and become exercisable financial

"stock options that vest and become exercisable for $2.075 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BJDX disclose about insider Svetlana Dey in this Form 4?

BJDX disclosed that director Svetlana Dey received a grant of 100,000 stock options with an exercise price of $2.075 per share, vesting after one year and expiring on August 17, 2031.

What are the vesting terms of the 100,000 BJDX stock options granted to Svetlana Dey?

The 100,000 BJDX stock options granted to Dey vest and become exercisable on the first anniversary of the grant date. However, exercise is also conditioned on FDA clearance or approval of the Symphony IL-6 device.

What is the exercise price of the stock options granted to the BJDX director?

The stock options granted to the BJDX director have an exercise price of $2.075 per share. They are described as out-of-the-money options and relate to 100,000 shares of Bluejay Diagnostics common stock.

Are the BJDX stock options granted to Svetlana Dey immediately exercisable?

No. The options are not immediately exercisable; they vest after one year and are additionally conditioned so they shall not be exercisable until the FDA grants clearance or approval of the Symphony IL-6 point-of-care testing device.

How many BJDX options does Svetlana Dey hold after this reported transaction?

After the reported transaction, Svetlana Dey holds 100,000 stock options directly. These options relate to BJDX common stock, carry a $2.075 exercise price, and expire on August 17, 2031, subject to vesting and FDA-related conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:16 PM Accepted by SEC EDGAR 08/18/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dey Svetlana

(Last) (First) (Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON MASSACHUSETTS 01720

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.075	08/17/2026		A		100,000		(1)	08/17/2031	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

	/s/ Svetlana Dey	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)